By early 1950, short-term corticotropin treatment at modest dosage levels was shown to give only incomplete or transient improvement in the more serious acute disorders of the posterior ocular segment or optic nerve, while, in more chronic eye diseases, it seldom gave any significant relief. In an attempt to improve upon these results, we began a study of the response to intensive long-acting corticotropin treatment, fully individualized both in dosage and duration of therapy. Originally, there were envisioned only trials in patients with those acute eye diseases which had been reported to respond unsatisfactorily to hormonal treatment. However, as the study progressed, it occasionally became necessary to treat a patient who presented suitable acute lesions in one eye and older, apparently inactive, clinically irreversible lesions in the other eye as a result of previous attacks of the same illness. In several such patients, the first of whom is illustrated by
WOLFSON WQ, QUINN JR, SPEARMAN WF. Corticoid Therapy in Eye Diseases: Sustained Restoration of Vision in Certain Eye Diseases Considered Corticoid-Refractory or Clinically Irreversible. AMA Arch Intern Med. 1955;95(3):400–410. doi:10.1001/archinte.1955.00250090038006
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: